Evidence map›Paper›PMID 42347523›Full record

ArticleToxins2026

The Impact of OnabotulinumtoxinA on Oral Pain Medication Prescription Fills and Low-Value Care in Patients with Cervical Dystonia in the United States: A Retrospective Claims Analysis.

Christopher Rhyne, Annaliza Dominguez, Ning Cheng, Shivaji Manthena, Krutika Parikh, Bahman Jabbari

Abstract read
In one paragraph

Article in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Christopher RhyneNorton Neuroscience Institute, Louisville, KY 40202, USA.
Annaliza DominguezAbbVie Inc., North Chicago, IL 60064, USA.
Ning ChengAbbVie Inc., North Chicago, IL 60064, USA.
Shivaji ManthenaAbbVie Inc., North Chicago, IL 60064, USA.
Krutika ParikhAbbVie Inc., North Chicago, IL 60064, USA.
Bahman JabbariDepartment of Neurology, Yale School of Medicine, New Haven, CT 06510, USA.ORCID 0000-0001-7204-8730

Funding

AbbVie (United States) N/A
6 · The paper itself

Abstract

(1) Background: While evidence supporting the use of onabotulinumtoxinA in patients with cervical dystonia (CD) is well-established, more evidence is needed to understand if onabotulinumtoxinA treatment can reduce reliance on addictive medication. (2) Methods: This retrospective study used claims data to evaluate the impact of onabotulinumtoxinA treatment on opioid, benzodiazepine (BZD), and skeletal muscle relaxant (SMR) prescription fills among patients diagnosed with CD with prior use of these medications. Among the 564 eligible patients, three non-mutually exclusive cohorts were identified based on medication use data: opioid (

Indexed as

Botulinum Toxins, Type APainTorticollisAdministration, OralAdultAgedAnalgesics, OpioidBenzodiazepinesDrug PrescriptionsFemaleHumansMaleMiddle AgedNeuromuscular AgentsRetrospective StudiesUnited StatesAnalgesics, OpioidBenzodiazepinesBotulinum Toxins, Type ANeuromuscular Agentsonabotulinum toxin Abenzodiazepinecervical dystoniaonabotulinumtoxinAopioidpainskeletal muscle relaxant

Identifiers

PMID42347523
PMCPMC13307583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.